JP2023543211A5 - - Google Patents
Info
- Publication number
- JP2023543211A5 JP2023543211A5 JP2023518735A JP2023518735A JP2023543211A5 JP 2023543211 A5 JP2023543211 A5 JP 2023543211A5 JP 2023518735 A JP2023518735 A JP 2023518735A JP 2023518735 A JP2023518735 A JP 2023518735A JP 2023543211 A5 JP2023543211 A5 JP 2023543211A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- days
- months
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/030,705 | 2020-09-24 | ||
| US17/030,705 US12090123B2 (en) | 2017-10-10 | 2020-09-24 | Extended release pharmaceutical formulation |
| PCT/IB2021/058647 WO2022064387A1 (en) | 2020-09-24 | 2021-09-22 | Extended release pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543211A JP2023543211A (ja) | 2023-10-13 |
| JP2023543211A5 true JP2023543211A5 (https=) | 2024-10-01 |
Family
ID=80846364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518735A Pending JP2023543211A (ja) | 2020-09-24 | 2021-09-22 | 徐放性医薬製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049734A1 (https=) |
| EP (1) | EP4216937A4 (https=) |
| JP (1) | JP2023543211A (https=) |
| KR (1) | KR20230074522A (https=) |
| CN (1) | CN116456972A (https=) |
| AU (1) | AU2021350581A1 (https=) |
| CA (1) | CA3190204A1 (https=) |
| MX (1) | MX2023003369A (https=) |
| WO (1) | WO2022064387A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10869838B2 (en) * | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| WO2024171074A1 (en) * | 2023-02-15 | 2024-08-22 | Clearmind Medicine Inc. | Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof |
| WO2025099182A1 (en) * | 2023-11-07 | 2025-05-15 | HMNC Holding GmbH | Induction regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one |
| WO2025099181A1 (en) * | 2023-11-07 | 2025-05-15 | HMNC Holding GmbH | Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2922507C (en) * | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| DK3215147T3 (da) * | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CN111630026A (zh) * | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
-
2021
- 2021-09-22 WO PCT/IB2021/058647 patent/WO2022064387A1/en not_active Ceased
- 2021-09-22 CN CN202180072775.8A patent/CN116456972A/zh active Pending
- 2021-09-22 KR KR1020237013515A patent/KR20230074522A/ko active Pending
- 2021-09-22 EP EP21871786.6A patent/EP4216937A4/en active Pending
- 2021-09-22 JP JP2023518735A patent/JP2023543211A/ja active Pending
- 2021-09-22 CA CA3190204A patent/CA3190204A1/en active Pending
- 2021-09-22 MX MX2023003369A patent/MX2023003369A/es unknown
- 2021-09-22 AU AU2021350581A patent/AU2021350581A1/en active Pending
-
2024
- 2024-07-12 US US18/771,903 patent/US20250049734A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543211A5 (https=) | ||
| JP2021066744A5 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| JP2006504795A5 (https=) | ||
| JP2021527092A5 (https=) | ||
| CA2453263A1 (en) | Pharmaceutical compositions containing terbinafine and use thereof | |
| RU2010105122A (ru) | Композиции для ухода за полостью рта, продукты и способы применения | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| JP2010513320A5 (https=) | ||
| Gonzalez et al. | High dose vitamin C and influenza: a case report | |
| JP2022527359A5 (https=) | ||
| JP2025510369A5 (https=) | ||
| RU2007103306A (ru) | Композиции на основе ризедроната и способы их применения | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| Akhtar et al. | Local anesthetic drugs used in dentistry | |
| ES2611019T3 (es) | Tratamiento de las quemaduras solares usando analgésicos y antihistamínicos | |
| Reddy et al. | Ketorolac vs morphine for severe vaso-occlusive crisis in sickle cell disease: an open-label randomized controlled trial (KISS Study) | |
| JP2025504984A5 (https=) | ||
| JP2023011549A5 (https=) | ||
| MAY et al. | Parkinsonian reactions following chlorpromazine and reserpine: similar reactions in the same patients | |
| JP2024531799A5 (https=) | ||
| JP2025522146A5 (https=) | ||
| JP2023533472A5 (https=) | ||
| US10046052B2 (en) | Method and formulation for cold treatment in adults and children with increased safety |